Chardan Capital initiated coverage on shares of Novartis AG (NYSE:NVS) in a research note issued to investors on Tuesday. The brokerage issued a buy rating and a $95.00 price target on the stock.

A number of other research analysts have also weighed in on NVS. Citigroup Inc. reaffirmed a neutral rating on shares of Novartis AG in a report on Tuesday, May 24th. JPMorgan Chase & Co. reaffirmed a buy rating on shares of Novartis AG in a report on Thursday, May 26th. Zacks Investment Research raised Novartis AG from a sell rating to a hold rating in a report on Wednesday, June 15th. TheStreet raised Novartis AG from a hold rating to a buy rating in a report on Friday, June 24th. Finally, Bank of America Corp. reiterated a hold rating on shares of Novartis AG in a research report on Tuesday, July 12th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Novartis AG presently has an average rating of Hold and an average target price of $91.83.

Shares of Novartis AG (NYSE:NVS) opened at 81.06 on Tuesday. The stock has a 50 day moving average of $80.80 and a 200-day moving average of $78.33. Novartis AG has a 12 month low of $69.90 and a 12 month high of $95.11. The company has a market cap of $193.02 billion, a PE ratio of 28.94 and a beta of 0.58.

Novartis AG (NYSE:NVS) last posted its earnings results on Tuesday, July 19th. The company reported $1.23 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.18 by $0.05. The business earned $12.47 billion during the quarter, compared to analyst estimates of $12.33 billion. Novartis AG had a return on equity of 15.33% and a net margin of 13.84%. During the same quarter in the previous year, the firm earned $1.25 EPS. Equities analysts forecast that Novartis AG will post $4.73 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in the company. Integrated Investment Consultants LLC increased its stake in Novartis AG by 6.3% in the second quarter. Integrated Investment Consultants LLC now owns 1,240 shares of the company’s stock worth $102,000 after buying an additional 74 shares during the last quarter. Whitnell & Co. increased its stake in Novartis AG by 14.6% in the second quarter. Whitnell & Co. now owns 1,410 shares of the company’s stock worth $116,000 after buying an additional 180 shares during the last quarter. Iowa State Bank purchased a new stake in Novartis AG during the second quarter worth $122,000. M&R Capital Management Inc. purchased a new stake in Novartis AG during the second quarter worth $122,000. Finally, WFG Advisors LP increased its stake in Novartis AG by 8.9% in the second quarter. WFG Advisors LP now owns 1,624 shares of the company’s stock worth $134,000 after buying an additional 133 shares during the last quarter. Institutional investors own 9.78% of the company’s stock.

Novartis AG Company Profile

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

5 Day Chart for NYSE:NVS

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.